Neuren Pharmaceuticals (ASX: NEU) has had massive turnover today with nearly 11 million shares changing hands, with the stock adding 14.3% to $0.12.
There haven't been any announcements from the company for well over a week, but the stock has been generating a lot of chatter on trading forums regarding possible results from the company's clinical trial on Rett Syndrome.
In regards to Neuren's Phase 2 clinical trial of NNZ-2566, the company said that clinical benefit, if any, of NNZ-2566 compared to placebo will not be known until treatment assignment is unblinded and the trial data are analysed.
This is anticipated to be in the second half of 2014.
Rett Syndrome severely affects speech and movement, and is a genetic disorder of the nervous system - which is usually only seen in girls and affects all body movement.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.